Atlas

Mirion Technologies jumped 5.4% recently, and the nuclear energy narrative it rides isn't cooling off anytime soon. With the stock sitting at $18.61 — just a hair above its 50-day moving average of $1

Mirum Pharmaceuticals is not a name that shows up in most retail traders' watchlists. That's usually where the interesting trades live. With a positive Phase 2 readout in hand, an NDA under active FDA

Pharvaris isn't a household name, but its lead drug — deucrictibant — is quietly building a compelling case in hereditary angioedema (HAE). With fresh clinical data just presented at EAACI 2026 and an

TGS — Transportadora de Gas del Sur — doesn't get the cocktail party chatter that domestic energy names do. It's an Argentine natural gas pipeline and NGL processor, priced in ADR form, and it trades

Denali Therapeutics just served up a perfect example of why biotech volatility creates premium opportunities. The stock dropped after their Biogen-partnered Parkinson's trial failed, but we're betting

Kimball Electronics is having an identity crisis in the market, and we're here for it. Trading 13% below its 200-day moving average at $24.80 while analysts maintain a $32 price target, KE offers the

Digi International is having a moment. The IoT infrastructure company just dropped three product announcements in rapid succession, expanding its Digi Axess platform with native remote access and laun

While Bitcoin slides to five-week lows and the S&P bleeds for its third straight day, we're selling a $12.50 put on ETHE expiring July 2026 for $0.33. The Grayscale Ethereum Trust offers a cleaner way

While headlines scream about private credit's cooling boom and redemption fears, we're taking the contrarian path on Blue Owl Capital (OWL). The market's panic over slowing private equity flows has cr

Sometimes the market serves up a ticker so obscure you wonder if it's a typo. ABNG sits at $16, offering 50 cents for selling the June 2026 put at that exact strike. Zero news, zero fundamentals, zero